Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne LJ, Horn DB, le Roux CW, et al. New England Journal of Medicine 2025;393:26-36.
What it found
Mean weight change was -20.2% with tirzepatide vs -13.7% with semaglutide, and waist circumference fell by 18.4 cm vs 13.0 cm. Gastrointestinal side effects were the most common with both drugs, mostly during dose escalation.
Limitations
Open-label, with no placebo group. Adults with obesity but without diabetes. Funded by the maker of tirzepatide.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.